Biotech company Eradivir is developing lead drug EV25 to treat influenza
Purdue News
Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low’s lab at Purdue University to focus on a platform of immunotherapies for viral infections like influenza and other diseases.
Read More
July 9, 2024